Notice: This company has been marked as potentially delisted and may not be actively trading. TF Financial (THRD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends THRD vs. EVO, TVTX, GPCR, SDGR, XNCR, ARDX, NRIX, KNSA, RCUS, and OCULShould you be buying TF Financial stock or one of its competitors? The main competitors of TF Financial include Evotec (EVO), Travere Therapeutics (TVTX), Structure Therapeutics (GPCR), Schrödinger (SDGR), Xencor (XNCR), Ardelyx (ARDX), Nurix Therapeutics (NRIX), Kiniksa Pharmaceuticals (KNSA), Arcus Biosciences (RCUS), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical preparations" industry. TF Financial vs. Evotec Travere Therapeutics Structure Therapeutics Schrödinger Xencor Ardelyx Nurix Therapeutics Kiniksa Pharmaceuticals Arcus Biosciences Ocular Therapeutix TF Financial (NASDAQ:THRD) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, community ranking, media sentiment, analyst recommendations, profitability and dividends. Do institutionals & insiders have more ownership in THRD or EVO? 94.0% of TF Financial shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 5.9% of TF Financial shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts rate THRD or EVO? TF Financial presently has a consensus target price of $20.33, suggesting a potential upside of 238.89%. Evotec has a consensus target price of $5.93, suggesting a potential upside of 43.66%. Given TF Financial's stronger consensus rating and higher possible upside, equities research analysts plainly believe TF Financial is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TF Financial 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Evotec 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, THRD or EVO? TF Financial has a beta of 2.75, meaning that its share price is 175% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Does the media favor THRD or EVO? In the previous week, Evotec had 3 more articles in the media than TF Financial. MarketBeat recorded 3 mentions for Evotec and 0 mentions for TF Financial. Evotec's average media sentiment score of 0.78 beat TF Financial's score of 0.00 indicating that Evotec is being referred to more favorably in the news media. Company Overall Sentiment TF Financial Neutral Evotec Positive Does the MarketBeat Community believe in THRD or EVO? TF Financial received 55 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 67.78% of users gave TF Financial an outperform vote while only 54.55% of users gave Evotec an outperform vote. CompanyUnderperformOutperformTF FinancialOutperform Votes6167.78% Underperform Votes2932.22% EvotecOutperform Votes654.55% Underperform Votes545.45% Which has stronger earnings & valuation, THRD or EVO? TF Financial has higher earnings, but lower revenue than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTF FinancialN/AN/A-$30.82M-$0.62-9.68Evotec$845.74M1.73-$90.82MN/AN/A Is THRD or EVO more profitable? Evotec's return on equity of 0.00% beat TF Financial's return on equity.Company Net Margins Return on Equity Return on Assets TF FinancialN/A -9.31% -9.03% Evotec N/A N/A N/A SummaryTF Financial beats Evotec on 9 of the 14 factors compared between the two stocks. Get TF Financial News Delivered to You Automatically Sign up to receive the latest news and ratings for THRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THRD vs. The Competition Export to ExcelMetricTF FinancialPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$260.89M$6.55B$5.39B$9.24BDividend YieldN/A2.96%5.37%3.99%P/E RatioN/A9.8989.1117.52Price / SalesN/A334.651,221.8479.25Price / CashN/A64.1243.6036.96Price / Book0.905.105.014.72Net Income-$30.82M$154.66M$117.81M$224.61M TF Financial Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THRDTF Financial1.8522 of 5 stars$6.00+3.6%$20.33+238.9%-40.4%$260.89MN/A0.00N/AEVOEvotec1.8719 of 5 stars$4.18-4.1%$5.93+41.9%-47.3%$1.48B$777.05M0.004,200News CoverageTVTXTravere Therapeutics2.08 of 5 stars$18.59+2.8%$23.67+27.3%+122.7%$1.45B$203.45M-4.09460Analyst RevisionGPCRStructure Therapeutics1.5076 of 5 stars$25.16-0.4%$81.29+223.1%-30.5%$1.44BN/A-34.00136Short Interest ↑SDGRSchrödinger1.8086 of 5 stars$19.47+0.9%$32.90+69.0%-19.1%$1.42B$193.35M-8.32790Options VolumeNews CoverageXNCRXencor4.1049 of 5 stars$20.26-1.7%$36.56+80.4%+4.1%$1.42B$85.16M-6.33280ARDXArdelyx3.6382 of 5 stars$5.88+16.0%$9.25+57.3%-40.7%$1.39B$251.85M-19.6090Analyst RevisionHigh Trading VolumeNRIXNurix Therapeutics2.293 of 5 stars$19.01+4.2%$30.35+59.7%+140.2%$1.35B$56.42M-6.53300Analyst ForecastNews CoverageKNSAKiniksa Pharmaceuticals2.8993 of 5 stars$18.17-8.8%$36.60+101.4%-0.9%$1.31B$384.10M-129.78220RCUSArcus Biosciences2.0087 of 5 stars$13.98-1.5%$34.00+143.2%-8.0%$1.28B$263M-4.44500Analyst RevisionNews CoverageOCULOcular Therapeutix3.5254 of 5 stars$8.12-1.1%$16.71+105.8%+110.1%$1.28B$61.44M-6.15230 Related Companies and Tools Related Companies Evotec Competitors Travere Therapeutics Competitors Structure Therapeutics Competitors Schrödinger Competitors Xencor Competitors Ardelyx Competitors Nurix Therapeutics Competitors Kiniksa Pharmaceuticals Competitors Arcus Biosciences Competitors Ocular Therapeutix Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:THRD) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TF Financial Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share TF Financial With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free THRD Stock Alerts